Full Press Release Details
AtriCure Names Sven Wehrwein to its Board of Directors
MASON, Ohio, November 11, 2016 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein has been appointed to its Board of Directors.
Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. He has more than 35 years of experience as an investment banker, chief financial officer, and certified public accountant. Wehrwein currently sits on the boards of several companies, including Proto Labs, Inc. and SPS Commerce, Inc. In addition, he has served as a Director for a number of other medical device and high growth companies including tenures on the boards of Compellent Technologies, Synovis Life Technologies, and Vital Images.
Sven has a wealth of experience that will be beneficial to the company, said Mike Carrel, President and CEO of AtriCure. He brings a deep level of expertise in corporate finance, accounting and strategy, and has been on the Boards of numerous successful public companies. We are fortunate to have him on our Board.
I am pleased to be joining the AtriCure Board, added Wehrwein. It is an exciting time for the company, which is well positioned to continue being a leader in the Afib and LAA markets. I look forward to doing my part to help guide continued growth.
Senior Vice President and Chief Financial Officer
Investor Relations Contact